Barry Richard purchased $207K of FLNA (indirect holdings)
Barry Richard (President & CEO) purchased 440,206 indirectly-held shares of FILANA THERAPEUTICS, INC. (FLNA) at $0.47 ($0.21M total) on 2026-11-16.
FILANA THERAPEUTICS, INC.
Filana Therapeutics is a clinical-stage biotechnology company headquartered in Austin, Texas. It develops drug candidates for central nervous system disorders, including Tuberous Sclerosis Complex-related epilepsy and other conditions associated with filamin A dysregulation or overexpression. Its scientific approach focuses on modulating filamin A, a scaffolding protein found in the brain and elsewhere in the body. Filana’s lead product candidate is simufilam, a proprietary oral small molecule designed in-house and studied for TSC-related epilepsy. The company is pursuing development of simufilam and exploring other potential indications. It owns or controls intellectual property related to simufilam and holds an exclusive worldwide license from Yale University to certain rights relevant to its development and commercialization. Filana outsources formulation, manufacturing and related activities to third parties, including clinical-grade drug supply. It discontinued its Alzheimer’s disease development program in the second quarter of 2025 and ended development of its SavaDx blood-based Alzheimer’s detection program in mid-2025.
Barry Richard (President & CEO) purchased 440,206 indirectly-held shares of FILANA THERAPEUTICS, INC. (FLNA) at $0.47 ($0.21M total) on 2026-11-16.
Schoen Eric (Chief Financial Officer) purchased 20,000 shares of FILANA THERAPEUTICS, INC. (FLNA) at $0.42 on 2026-11-16.
Cook Robert Christopher (Chief Operating& Legal Officer) purchased 121,575 shares of FILANA THERAPEUTICS, INC. (FLNA) at $0.46 on 2026-11-16.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning FLNA (FILANA THERAPEUTICS, INC.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent FLNA coverage spans insider activity, financial news and earnings.
In the last 30 days, FLNA insiders filed 3 SEC Form 4 transactions — 3 purchases ($271K) and no sales. The most active reporter was Barry Richard, President & CEO, with 1 filing.
Insider open-market buying can be read as confidence, but this is a modest-sized transaction and lacks a 10b5-1 plan disclosure.
Insider open-market purchase is modest in dollar terms and typically signals mild bullish sentiment, but is unlikely to drive near-term price action alone.
The filing is a modest insider open-market buy that may be read as confidence, but the dollar size is small and unlikely to drive price by itself.
Board addition may be viewed positively, modestly supporting the stock.
Minor governance update with limited immediate market effect.
AlphAI scores every news story that mentions FLNA with an AI model for sentiment and relevance, and aggregates insider trades from FILANA THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Barry Richard (President & CEO) purchased 440,206 indirectly-held shares of FILANA THERAPEUTICS, INC. (FLNA) at $0.47 ($0.21M total) on 2026-11-16.
Schoen Eric (Chief Financial Officer) purchased 20,000 shares of FILANA THERAPEUTICS, INC. (FLNA) at $0.42 on 2026-11-16.
Cook Robert Christopher (Chief Operating& Legal Officer) purchased 121,575 shares of FILANA THERAPEUTICS, INC. (FLNA) at $0.46 on 2026-11-16.
FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Filana Therapeutics Names Biopharma Executive Jill M. Quigley to Board –Appointment brings leadership experience building and financing biopharma companies AUSTIN, Texas, November 11, 2026 (GLOBE NEWSWIRE) –– Filana Therapeutics, Inc. (NASDAQ: FLNA), a biotechnology
Filana Therapeutics (FLNA) added Jill M. Quigley to its board. The company expects to start patient screening for its Phase 2a simufilam study in TSC-related epilepsy by Q1 2027, according to the company.
Filana Therapeutics reported a Q3 2026 net loss of $10.7M, or $0.22 per share, with $47M in cash. The FDA lifted a clinical hold on simufilam for TSC-related epilepsy, and a Phase 2a study is expected to begin by Q1 2027. R&D expenses were $3.9M, down from $4M a year earlier. The company expects year-end cash to be $38M-$42M.
FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update – Patient screening in Phase 2a study of simufilam in TSC-related epilepsy expected to begin by Q1 2027, following recent lift of FDA clinical hold – Recent publication in Cells 1 prov
Filana Therapeutics (FLNA) announced preclinical research showing its drug candidate, simufilam, improved cellular stress responses and mitochondrial function in TSC2-deficient cells. The company plans to start a Phase 2a study for TSC-related epilepsy by Q1 2027. According to Yale researchers, simufilam reduced ATF4 expression by 37% and restored mitochondrial membrane potential. The findings suggest a potential mechanism distinct from mTOR inhibition.
Filana Therapeutics won a vacatur of class certification in a securities suit by the Fifth Circuit, which found the Texas District Court misapplied legal standards. The case was remanded for further proceedings, with the appellate panel noting market inefficiency and meme-stock dynamics were not adequately considered. According to the Fifth Circuit, the district court did not properly evaluate evidence. Filana Therapeutics (FLNA) is the subject company.
FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On October 16, 2026, the United States Court of Appeals for the Fifth Circuit (the “Fifth Circuit”) vacated the order of the U.S. District Court for the Western District of Texas (the “Texas District Court”) granting class certification in the securities